What Technologies Will Be Replaced By Chemiluminiscence POCT (Point-of-Care Testing)?

  • 2019-03-18

Incorporating the high sensitivity of chemiluminiscence and high specificity of immunoassay, the chemiluminescence immunoassay is widely used in clinical trial, pharmaceutical analysis, environmental monitoring, etc. Chemiluminiscence test is characterized by high sensitivity, wide test scope and good reproducibility. The relevant instruments and reagents are of high precision. Thanks to those advantages, the automated chemiluminescence immunoassay analyzer has become the main equipment to perform immunoassay in laboratories in large hospitals. The chemiluminiscence POCT indicates the application of chemiluminescence immunoassay in POCT. This kind of combination is made due to that lateral flow immunoassays fail to meet the growing clinical requirement in sensitivity and precision. What’s worse, automated chemiluminescence immunoassay analyzer and its reagent can’t compete directly against the 4 giants, Beckman, Roche, Abbott and Siemens.

Offense and defense of traditional POCT manufacturers: according to the performance reports of the 3 listed POCT manufacturers, they all keep a stable performance. Such giants in chemiluminescence as Autobio, Maccura, Mindray, Snibe, etc. are increasing their shares in the POCT market, and some small POCT manufacturers are also sparing no effort to catch up. Under that circumstance, three POCT manufacturers distribute their business in advance. Wondfo ranks 1 in both business volume and growth speed. Multiple strategies it applies have maintained its market competitiveness. Wondfo manages to expand its market by diverse and differentiated detection products. By putting efforts in influenza virus detection, drug detection and substance abuse with government, Wondfo successfully expands its business beyond medical health. Furthermore, by acquiring Diacha Dignostics, Wondfo has also completed its market arrangement of chemiluminescence products. Getein Biotech and Wuhan Easydiagnosis Biomedicine Co., Ltd. rank respectively 2nd and 3rd in both POCT business volume and growth speed. The 2 companies have both set out some arrangements in chemiluminescence market. Getein Biotech is relying on self-developed instruments and reagents to expand its business. Registration certificate has been approved to fully automatic chemiluminescence immunoassay analyzer MAGICL6800 in 2015. Putting reagents at its core, Wuhan Easydiagnosis Biomedicine Co., Ltd., based on the small chemiluminescence instrument SMART300, is devoted to the development of reagents, so as to expand its business in POCT detection.

In my opinions, chemiluminescence POCT is indeed conducive to the improvement of detection sensitivity and reliability, but we still need time to popularize that new technology and concept, especially in those fields that keep a conservative attitude towards medical devices. Moreover, the application of lateral flow immunoassays in POCT is still perfectable and marketable. The competition between the two will continue to be an open topic in the coming 5 to 10 years.